Amniotic fluid stem cell administration can prevent epithelial injury from necrotizing enterocolitis

Area of Science:

• Regenerative Medicine
• Neonatal Research
• Gastroenterology

Background:

• Necrotizing enterocolitis (NEC) is a severe intestinal injury in neonates.
• Stem cell therapy, particularly with amniotic fluid-derived stem cells (AFSCs) and bone marrow-derived mesenchymal stem cells (MSCs), shows potential for treating experimental NEC.
• Understanding the distinct mechanisms of AFSCs and MSCs is crucial for developing effective preventative strategies.

Purpose of the Study:

• To compare the effects of AFSCs and MSCs on preventing intestinal injury in experimental NEC.
• To investigate the underlying mechanisms, including proteomic profiles and cellular responses, of AFSCs and MSCs in the context of NEC.

Main Methods:

• Proteomic analysis of AFSC and MSC supernatants to identify distinct protein profiles.
• Administration of AFSCs or MSCs to mice prior to NEC induction.
• Assessment of NEC severity, mucosal inflammation, intestinal proliferation, and endogenous stem cell activation.

Main Results:

• AFSCs exhibited faster growth and were primarily involved in cell development and growth, while MSCs were associated with immune regulation.
• Pre-treatment with AFSCs significantly reduced NEC severity and mucosal inflammation.
• AFSC administration increased intestinal proliferation and endogenous stem cell activation, whereas MSCs showed no beneficial effects.

Conclusions:

• AFSCs and MSCs possess distinct protein secretory profiles and functional roles.
• AFSCs demonstrate potential as a preventative therapy for NEC by enhancing intestinal epithelial cell growth and offering protection against injury.
• Further evaluation of AFSCs for NEC prevention in at-risk infants is warranted.